- Previous Close
4.9600 - Open
4.9600 - Bid 4.9500 x 900
- Ask 4.9700 x 1600
- Day's Range
4.9400 - 4.9700 - 52 Week Range
2.2900 - 5.4950 - Volume
642,444 - Avg. Volume
1,216,735 - Market Cap (intraday)
259.939M - Beta (5Y Monthly) 1.05
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1000 - Earnings Date May 1, 2025 - May 5, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma. It has a collaboration arrangement with Bristol Myers Squibb Company. 2seventy bio, Inc. was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
www.2seventybio.comRecent News: TSVT
View More
Performance Overview: TSVT
Trailing total returns as of 4/11/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TSVT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TSVT
View MoreValuation Measures
Market Cap
259.07M
Enterprise Value
328.04M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
6.83
Price/Book (mrq)
1.23
Enterprise Value/Revenue
8.66
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-151.20%
Return on Assets (ttm)
-12.62%
Return on Equity (ttm)
-24.56%
Revenue (ttm)
37.86M
Net Income Avi to Common (ttm)
-57.25M
Diluted EPS (ttm)
-1.1000
Balance Sheet and Cash Flow
Total Cash (mrq)
174.75M
Total Debt/Equity (mrq)
115.61%
Levered Free Cash Flow (ttm)
-62.54M